GLPBio

Immunology/Inflammation

Read More about this category

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

Research Areas

Products Related to Immunology/Inflammation(4792)

  • GC74304 structure
    GC74304PSMA targeting peptide TFA
    Purity: >99.00%

    PSMA targeting peptide TFA (PSMA - 1 TFA) est un peptide ciblé par la PSMA (grfltggtgrlllris) qui peut être utilisé pour délivrer de manière ciblée des sirna silencieux de la protéine de régulation du glucose (GRP) dans les cellules PCA.

  • GC74307 structure
    GC743073BP-3940
    CAS: 2803421-14-7
    Purity: >99.00%

    3BP-3940 est un peptide de ciblage de la protéine d'activation des fibroblastes (FAP) hautement efficace pour le diagnostic thérapeutique.

  • GC74313 structure
    GC74313MYBMIM
    Purity: >99.00%

    MYBMIM est un inhibiteur pour l’assemblage du complexe moléculaire MYB:CBP/P300.

  • GC74317 structure
    GC74317S7
    CAS: 853248-13-2
    Purity: >99.00%

    S7 est un antagoniste des récepteurs de l'il - 6 qui inhibe la liaison entre l'il - 6 et l'il - 6r.

  • GC74335 structure
    GC74335Icotrokinra
    CAS: 2763602-16-8
    Purity: >99.00%

    Icotrokinra (JNJ-77242113) est un antagoniste sélectif oral du récepteur IL-23.

  • GC74339 structure
    GC74339Ac2-26 ammonium
    Purity: >98.00%

    Ac2-26 ammonium est le Peptide n - terminal de l'annexine 1, qui a une activité anti - inflammatoire.

  • GC74354 structure
    GC74354Pegcetacoplan acetate
    Purity: >98.00%

    Pegcetacoplan acetate est un peptide pégylé inhibiteur C3 du complément.

  • GC74402 structure
    GC74402HYNIC-iPSMA TFA
    CAS: 2375849-11-7
    Purity: >99.00%

    HYNIC-iPSMA TFA est un Ligand pour l'imagerie moléculaire des tumeurs. NIC ipsma est composé de deux composants: NIC (6 - oxazinonbutamide) et ipsma (inhibiteur de l'antigène membranaire spécifique de la prostate).

  • GC74423 structure
    GC74423Vamikibart
    CAS: 2744320-12-3
    Purity: >99.00%

    Vamikibart est un anticorps IgG2κ humanisé chimérique ciblant IL6.

  • GC74425 structure
    GC74425Casdozokitug
    CAS: 2643331-37-5
    Purity: >96.00%

    Casdozokitug (SRF-388) est un anticorps IgG1κ ciblant IL27.

  • GC74439 structure
    GC74439Picankibart
    CAS: 2622900-74-5
    Purity: >98.00%

    Picankibart est un anticorps IgG1κ dérivé de la souris ciblant IL23A.

  • GC74446 structure
    GC74446Rademikibart
    CAS: 2648260-80-2
    Purity: >98.00%

    Rademikibart (CBP-201) est un anticorps monoclonal humain ciblant l’il-4rα avec un KD de 20,7 pM lorsqu’il se lie à des épiopes humains d’il-4rα.

  • GC74451 structure
    GC74451Enfortumab vedotin-ejfv (solution)
    CAS: 1346452-25-2
    Purity: >99.00%

    Enfortumab vedotin-ejfv (solution) est un anticorps anti - nectin - 4 couplé à un médicament pour le traitement du cancer urothélial.

  • GC74457 structure
    GC74457Lunsekimig
    Purity: >98.00%

    Lunsekimig est un anticorps monoclonal anti-TSLP/IL13/ALB composé de 5 chaînes lourdes à région variable liées séquentiellement.

  • GC74471 structure
    GC74471Camidanlumab
    CAS: 921618-45-3
    Purity: >99.00%

    Camidanlumab (humax - tac) est un anticorps monoclonal cd25.

  • GC74476 structure
    GC74476Seribantumab
    CAS: 1334296-12-6
    Purity: >95.00%

    Seribantumab (mm 121) est un anticorps monoclonal igg2 entièrement humain qui cible her3.

  • GC74477 structure
    GC74477Tigatuzumab
    CAS: 918127-53-4
    Purity: >95.00%

    Tigatuzumab (CS - 1008) est un anticorps monoclonal humanisé IgG1 qui cible le récepteur de la mort 5 (dr5).

  • GC74482 structure
    GC74482Drozitumab
    CAS: 912628-39-8
    Purity: >99.00%

    Drozitumab (Pro 95780) est un anticorps monoclonal agoniste humain qui se lie au récepteur de la mort dr5.

  • GC74483 structure
    GC74483Galiximab
    CAS: 357613-77-5
    Purity: >99.00%

    Galiximab (IDEC 114) est un anticorps monoclonal primatisé d’immunoglobuline G1 (IgG1) lambda dirigé contre l’antigène CD80 et bloque la liaison CD80-CD28.

  • GC74486 structure
    GC74486Lexatumumab
    CAS: 845816-02-6
    Purity: >96.00%

    Lexatumumab (HgS - etr 2) est un anticorps monoclonal de type igg4 Kappa agoniste du récepteur Trail 2 (Trail - R2, dr5, Apo - 2).

  • GC74488 structure
    GC74488Sirukumab
    CAS: 1194585-53-9
    Purity: >95.00%

    Sirukumab (cnto - 136) est un anticorps monoclonal humanisé anti - IL6 (Interleukine - associated) IgG1 Kappa.

  • GC74490 structure
    GC74490Tositumomab
    CAS: 192391-48-3

    Tositumomab est un anticorps monoclonal murin igg2a λ dirigé contre l'antigène cd20, présent à la surface des lymphocytes B normaux et malins.

  • GC74491 structure
    GC74491Tucotuzumab
    CAS: 339986-90-2
    Purity: >95.00%

    Tucotuzumab (Anti-EPCAM Recombinant anticorps) est un anticorps monoclonal IgG1 spécifique à l’antigène qui cible la molécule d’adhésion des cellules épithéliales humaines (EpCAM).

  • GC74499 structure
    GC74499Talacotuzumab
    CAS: 1826831-79-1
    Purity: >98.00%

    Talacotuzumab (Jnj 56022473; CSL 362) est un anticorps monoclonal neutralisant cd123 entièrement humanisé de type IgG1 contenant une structure FC modifiée.